New updates have been reported about Ten63 Therapeutics.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ten63 Therapeutics has raised additional strategic financing from new investors including Chugai Venture Fund and the Gates Foundation, lifting its total funding to more than $45 million and adding Chugai’s Mike Dial, Ph.D., to its board. The capital will be used to scale Ten63’s BEYOND platform, described as a Large Quantum Chemistry Model that can simulate trillions of potential small molecules per protein with near experimental accuracy, enabling the company to pursue historically undruggable targets such as the Myc oncogene.
Backed by a dedicated grant from the Gates Foundation, Ten63 will also apply BEYOND to develop affordable small-molecule therapies for HPV-driven lesions and cervical cancer globally by attacking viral proteins that have resisted conventional drug approaches. Management positions BEYOND as a step toward drug-discovery superintelligence, supporting a pipeline of first- and best-in-class oncology candidates and select partnerships, with investors viewing the model’s ability to unlock data-poor, high-impact targets as a potential inflection point for both the company’s growth and broader drug development economics.